Stepping down inhaled corticosteroids from scheduled to as needed in stable asthma: Systematic review and meta-analysis

Allergy and Asthma Proceedings

Volumn 36, Issue 4, 2015, Pages 262-267

  Gionfriddo, Michael R ^a   Hagan, John B ^a   Hagan, Christina R ^b   Volcheck, Gerald W ^a   Castaneda Guarderas, Ana ^a   Rank, Matthew A ^c  

^a MAYO CLINIC   (United States)

^b BAYLOR UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; DISEASE EXACERBATION; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STABLE ASTHMA; SYSTEMATIC REVIEW; DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; ODDS RATIO; PUBLISHING; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG ADMINISTRATION SCHEDULE; HUMANS; ODDS RATIO; PUBLICATION BIAS; TREATMENT OUTCOME;

EID: 84938369592     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2015.36.3850     Document Type: Article

References (25)

1. Global Initiative for Asthma. Global strategy for asthma man-agem and p tion, 2012. Available from: http://www.ginasthma.org/
2. National Center for Environmental Health. Asthma's impact on the tion, 2012. http://www.cdc.gov/asthma/impactsnation/asthmafactsheet.pdf
3. Mahon AW, Levenson MS, McEvoy BW, et al. Age and risks of FDA-approved long-acting adrenergic receptor agonists. Pediatrics 128:e1147-e1154, 2011.
4. Powell H, and Gibson PG. Inhaled corticosteroid doses in asthma: An evidence-based approach. Med J Aust 178:223-225, 2003.
5. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2014. Available from: http://www.ginasthma.org/
6. National Heart Lung Blood Institute. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma- Full report. August 2007. http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf
7. Rank MA, Branda ME, McWilliams DB, et al. Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program. Ann Allergy Asthma Immunol 110:354-358.e352, 2013.
8. Hagan JB, Samant SA, Volcheck GW, et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials. Allergy 69:510-516, 2014.
9. Brozek JL, Kraft M, Krishnan JA, et al. Long-acting -2-agonist step-off in patients with controlled asthma. Arch Intern Med 172:1365-1375, 2012.
10. Rank MA, Hagan JB, Park MA, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 131:724-729, 2013.
11. Rank MA, Ziegenfuss JY, Shah KM, et al. Factors associated with decisions to step down asthma medications. J Allergy Clin Immunol Pract 1:312-314, 2013.
12. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 62:1006-1012, 2009.
13. PROSPERO. Centre for Reviews and Dissemination, University of York, York, United Kingdom. http://www.crd.york.ac.uk/PROSPERO
14. J. Eden, L. Levit, A. Berg, S. Morton, eds. Finding what works in health care: Standards for systematic reviews. Institute of Medicine. National Academies Press, Washington D.C.; 2011
15. Chauhan BF, Chartrand C, and Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2:CD009611, 2013.
16. Higgins JPT, and Green S (Eds). Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration, 2011. http://handbook.cochrane.org/
17. DerSimonian R, and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986.
18. Norman GR, Sloan JA, and Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 41:582-592, 2003.
19. Higgins JP, Thompson SG, Deeks JJ, and Altman DG. Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003.
20. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): A randomised, double-blind, placebo-controlled trial. Lancet 377:650-657, 2011.
21. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 356:2040-2052, 2007.
22. Rodrigo GJ, and Castro-Rodriguez JA. Daily vs. intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma: A systematic review with meta-analysis. Respir Med 107:1133-1140, 2013.
23. Rank MA, and Peters SP. The risks, benefits, and uncertainties of stepping down asthma medications. J Allergy Clin Immunol Pract 2:503-509, quiz 510, 2014.
24. Zhang L, Prietsch SO, and Ducharme FM. Inhaled corticosteroids in children with persistent asthma: Effects on growth. Cochrane Database Syst Rev 7:CD009471, 2014.
25. Pruteanu AI, Chauhan BF, Zhang L, et al. Inhaled corticosteroids in children with persistent asthma: Dose-response effects on growth. Cochrane Database Syst Rev 7:CD009878, 2014.